Liquidia (LQDA) Competitors $10.98 +0.13 (+1.20%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LQDA vs. HRTX, PDEX, DRRX, DRIO, XAIR, NVST, LIVN, NARI, IRTC, and ENOVShould you be buying Liquidia stock or one of its competitors? The main competitors of Liquidia include Heron Therapeutics (HRTX), Pro-Dex (PDEX), DURECT (DRRX), DarioHealth (DRIO), Beyond Air (XAIR), Envista (NVST), LivaNova (LIVN), Inari Medical (NARI), iRhythm Technologies (IRTC), and Enovis (ENOV). These companies are all part of the "medical" sector. Liquidia vs. Heron Therapeutics Pro-Dex DURECT DarioHealth Beyond Air Envista LivaNova Inari Medical iRhythm Technologies Enovis Liquidia (NASDAQ:LQDA) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation. Do analysts recommend LQDA or HRTX? Liquidia currently has a consensus price target of $24.67, suggesting a potential upside of 124.65%. Heron Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 237.08%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Liquidia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liquidia 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.90Heron Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, LQDA or HRTX? Liquidia has higher earnings, but lower revenue than Heron Therapeutics. Liquidia is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLiquidia$14.84M56.82-$78.50M-$1.57-6.99Heron Therapeutics$127.04M2.13-$110.56M-$0.32-5.56 Is LQDA or HRTX more profitable? Heron Therapeutics has a net margin of -35.29% compared to Liquidia's net margin of -755.46%. Heron Therapeutics' return on equity of 0.00% beat Liquidia's return on equity.Company Net Margins Return on Equity Return on Assets Liquidia-755.46% -183.57% -74.19% Heron Therapeutics -35.29%N/A -21.68% Do institutionals & insiders have more ownership in LQDA or HRTX? 64.5% of Liquidia shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 30.1% of Liquidia shares are held by insiders. Comparatively, 5.8% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor LQDA or HRTX? Heron Therapeutics received 462 more outperform votes than Liquidia when rated by MarketBeat users. Likewise, 69.11% of users gave Heron Therapeutics an outperform vote while only 67.81% of users gave Liquidia an outperform vote. CompanyUnderperformOutperformLiquidiaOutperform Votes19867.81% Underperform Votes9432.19% Heron TherapeuticsOutperform Votes66069.11% Underperform Votes29530.89% Does the media prefer LQDA or HRTX? In the previous week, Heron Therapeutics had 1 more articles in the media than Liquidia. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for Liquidia. Liquidia's average media sentiment score of 0.59 beat Heron Therapeutics' score of 0.31 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, LQDA or HRTX? Liquidia has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. SummaryHeron Therapeutics beats Liquidia on 13 of the 19 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Liquidia News Delivered to You Automatically Sign up to receive the latest news and ratings for LQDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LQDA vs. The Competition Export to ExcelMetricLiquidiaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$843.20M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-6.999.93115.5615.18Price / Sales56.82381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book15.045.324.665.02Net Income-$78.50M$153.56M$119.06M$225.46M7 Day Performance-0.27%0.11%0.80%0.37%1 Month Performance9.75%15.22%5.65%3.57%1 Year Performance69.97%41.14%36.76%29.44% Liquidia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LQDALiquidia3.8771 of 5 stars$10.98+1.2%$24.67+124.7%+66.6%$843.20M$14.84M-6.9950Upcoming EarningsHRTXHeron Therapeutics3.6569 of 5 stars$1.85+3.9%$6.00+224.3%+183.1%$278.71M$136.36M-5.78300Positive NewsPDEXPro-Dex1.6249 of 5 stars$29.07+2.0%$30.00+3.2%+108.7%$96.51M$53.84M46.89140News CoverageGap UpDRRXDURECT2.7838 of 5 stars$1.43-1.4%$21.00+1,368.5%-55.0%$44.39M$8.41M-2.3480DRIODarioHealth2.1152 of 5 stars$0.97+3.2%$4.00+312.4%-6.2%$29.03M$19.15M-0.82200Upcoming EarningsXAIRBeyond Air4.5286 of 5 stars$0.40+2.6%$3.67+812.3%-79.0%$18.45M$1.78M-0.2570Gap DownNVSTEnvista4.3067 of 5 stars$18.89-0.7%$19.88+5.2%-8.9%$3.25B$2.53B-2.4512,800Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLIVNLivaNova4.2909 of 5 stars$53.00+0.2%$69.83+31.8%+2.2%$2.87B$1.21B-165.632,900Analyst ForecastNews CoverageNARIInari Medical3.1996 of 5 stars$43.70-0.6%$57.44+31.5%-20.6%$2.54B$547.47M-44.141,300Analyst ForecastInsider SellingAnalyst RevisionIRTCiRhythm Technologies3.0804 of 5 stars$75.68-3.1%$113.90+50.5%-4.9%$2.36B$492.68M-17.722,000Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageENOVEnovis2.955 of 5 stars$39.99+1.1%$67.00+67.5%-5.8%$2.19B$1.91B-24.096,550Upcoming Earnings Related Companies and Tools Related Companies Heron Therapeutics Competitors Pro-Dex Competitors DURECT Competitors DarioHealth Competitors Beyond Air Competitors Envista Competitors LivaNova Competitors Inari Medical Competitors iRhythm Technologies Competitors Enovis Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LQDA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liquidia Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liquidia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
